Item 7.01 Regulation FD Disclosure.

On January 18, 2022, Impel Neuropharma, Inc. (the "Company") issued a press release in which it announced an update to the Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) launch progress and recent business highlights. A copy of the press release is attached to this Current Report on Form 8-K (this "Report") as Exhibit 99.1 and is incorporated by reference into this Item 7.01.

On January 18, 2022, the Company updated its corporate presentation, which it intends to use as part of investor presentations. A copy of the presentation is attached to this Report as Exhibit 99.2 and is incorporated by reference into this Item 7.01.

The information in this Item 7.01 (including Exhibit 99.1 and 99.2 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No. Description 99.1* Press release dated January 18, 2022 99.2* Investor presentation, dated January 18, 2022 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)






* Furnished herewith.












                                       3

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses